ARRIS - Another partner | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
ARRIS - Another partner

An SI Board Since June 1996

Posts	SubjectMarks	Bans	Symbol
353	2	0	AXPH

Emcee: Paul Getman	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
328	The patent situation is not clear to me. There is a small company called Proto	John Metcalf	-	12/24/1997
327	Firewalls in any business are never high enough to reach the top. If this is a	CYBERKEN	-	12/24/1997
326	John: >>Miljenko, in which respect do you think ARRS/MRK are wasting mon	Miljenko Zuanic	-	12/24/1997
325	Miljenko, in which respect do you think ARRS/MRK are wasting money? It was cur	John Metcalf	-	12/23/1997
324	To all: Are ARRS/Merck wasting their time and our money? pnas.org mz	Miljenko Zuanic	-	12/23/1997
323	Hi Joe; You ask an important question that seems to have been lost with all the	Steve Lokness	-	12/15/1997
322	He Everyone, I just bought into ARRS and would like some thoughts from you abou	Joe C.	-	12/14/1997
321	John: Thanks for clearing up my wrong assessment. I was impressed with crystal	Miljenko Zuanic	-	12/13/1997
320	John: >>My question is why did ARRS feel the need to _buy_ a company? Wh	Miljenko Zuanic	-	12/13/1997
319	JD: The CEO told me at the annual shareholders meeting a couple of years ago t	David Bogdanoff	-	12/12/1997
318	Off topic... Miljenko, Chris is a post-doc in Bart deVos' lab who came t	John Dwyer	-	12/12/1997
317	>>I hope you will agree that target validation in drug development is as	John Dwyer	-	12/12/1997
316	John: >>Do you think that ARRS bought SQNA because it was a cheap way to	Miljenko Zuanic	-	12/11/1997
315	Miljenko, You have good perspective on the main issues here. Let me ask you t	John Dwyer	-	12/11/1997
314	Thanks Peter. Agree that ARRS was/is cheap at current level with or without SQ	Miljenko Zuanic	-	12/9/1997
313	chirodoc: I bought a little last week, but the biotechs are looking pretty sic	Biomaven	-	12/9/1997
312	<<<<<The other possibility is that the selling pressure from the	chirodoc	-	12/9/1997
311	<<<<<Combine company will benefit from each part because fields	chirodoc	-	12/9/1997
310	Miljenko & others: Here's one possibility as to why Arris shot up on t	Biomaven	-	12/9/1997
309	JG: SQNA is not pure genomic company. If you do some basic reading the propose	Miljenko Zuanic	-	12/9/1997
308	Doc: I said for now. Their obviously attention is to get out of ARRS, but no	Miljenko Zuanic	-	12/9/1997
307	<<<<<. But don't take either of their words for it -- get th	chirodoc	-	12/9/1997
306	Alas, the disaffected didn't have time to vote with their feet. Arris stoc	JG	-	12/9/1997
305	<<<<<< Perhaps the disaffected have already mostly voted with	chirodoc	-	12/8/1997
304	<<<<<<At least we have signal that their sell-off is done for	chirodoc	-	12/8/1997

Go to reply# or date (mm/dd/yy):